NEUROSCIENTIFIC BIOPHARMACEUTICALS LIMITED

Highlights NeuroScientific Biopharmaceuticals Limited

Equities

NSB

AU0000012973

Delayed Australian S.E. Other stock markets 07:10:57 27/05/2024 BST			5-day change	1st Jan Change
0.043 ^AUD	0.00%		-6.52%	-2.27%

03-20	NeuroScientific Biopharmaceuticals Secures AU$2 Million R&D Tax Rebate for Fiscal Year 2023; Shares Rise 6%	MT
02-27	NeuroScientific Biopharmaceuticals Limited Reports Earnings Results for the Half Year Ended December 31, 2023	CI

Highlights

Unlock all the news: Be the first to know and act before the market!

100% Free Registration

NeuroScientific Biopharmaceuticals Secures AU$2 Million R&D Tax Rebate for Fiscal Year 2023; Shares Rise 6%	03-20	MT
NeuroScientific Biopharmaceuticals Limited Reports Earnings Results for the Half Year Ended December 31, 2023	02-27	CI
Neuroscientific Biopharmaceuticals Limited Announces Board Changes	11-12	CI
NeuroScientific Biopharmaceuticals Limited Reports Earnings Results for the Full Year Ended June 30, 2023	25/08/23	CI
Neuroscientific Biopharmaceuticals Announce Positive Treatment Effect in Multiple sclerosis Animal Study	14/03/23	CI
NeuroScientific Biopharmaceuticals Limited Reports Earnings Results for the Half Year Ended December 31, 2022	27/02/23	CI
NeuroScientific Biopharmaceuticals Files A New Patent, Entitled "Neuroprotective Compositions and Methods"	04/12/22	CI
Neuroscientific Biopharmaceuticals Ltd. Announces HREC Decision to Not Approve Phase I Clinical Trial	06/09/22	CI
NeuroScientific Biopharmaceuticals Limited Reports Earnings Results for the Full Year Ended June 30, 2022	29/08/22	CI
Neuroscientific Biopharmaceuticals Files Ethics Application for Phase 1 Trial of Neuroprotective Drug	12/07/22	MT
NeuroScientific Biopharmaceuticals Limited Announces Human Research Ethics Committee Submission for Phase I Clinical Trial	12/07/22	CI
NeuroScientific Biopharmaceuticals Limited Announces Recruitment of First Subject Recruited for Early-Phase Clinical Trial	30/06/22	CI
NeuroScientific Biopharmaceuticals Limited Announces Clarification of Results in Ms Animal Study	21/06/22	CI
NeuroScientific Biopharmaceuticals Limited Announces Positive Preliminary Results of Lead Drug Candidate EMTINB	14/06/22	CI
Neuroscientific Biopharmaceuticals Ltd Receives Approval from the Human Research Ethics Committee for its Early-Phase Clinical Trial of Lead Drug Candidate EmtinBTM	07/06/22	CI
Neuroscientific Biopharmaceuticals Files Ethics Submission for Neuroprotective Drug	12/05/22	MT
Neuroscientific Biopharmaceuticals Limited Announces Submission for HREC Approval of Early-Phase Clinical Trial of EmtinBTM	11/05/22	CI
NeuroScientific Biopharmaceuticals Limited Announces Positive Safety Result Supports Advance to Clinical Trials	13/04/22	CI
NeuroScientific Biopharmaceuticals Limited Announces Results from A Recently Completed Assessment of Lead Drug Candidate EmtinB in Human Primary Cell-Based Systems	10/03/22	CI
NeuroScientific Biopharmaceuticals Limited Reports Earnings Results for the Half Year Ended December 31, 2021	27/02/22	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights NeuroScientific Biopharmaceuticals Limited

Equities

NSB

AU0000012973

Highlights

Filters